Medical releases
Medical releases
Results 1 – 10 of 113 for LYNPARZA (3.50 seconds)
Oncology
Oncology
AstraZeneca and Foundation Medicine enter strategic collaboration for Lynparza companion diagnostic assay
AstraZeneca and Foundation Medicine enter strategic collaboration for Lynparza companion diagnostic assay
Lynparza approved in Japan for BRCA-mutated metastatic breast cancer
Lynparza approved in Japan for BRCA-mutated metastatic breast cancer
Lynparza approved in Japan for BRCA-mutated metastatic breast cancer
Lynparza approved in Japan for BRCA-mutated metastatic breast cancer
Lynparza receives approval in Japan for the treatment of advanced ovarian cancer
Lynparza receives approval in Japan for the treatment of advanced ovarian cancer
Lynparza nearly doubled the time patients lived without disease progression from germline BRCA-mutated metastatic pancreatic cancer
Lynparza nearly doubled the time patients lived without disease progression from germline BRCA-mutated metastatic pancreatic cancer
Lynparza™approved in the European Union as first-in-class treatment for advanced BRCA-mutated ovarian cancer
Lynparza™approved in the European Union as first-in-class treatment for advanced BRCA-mutated ovarian cancer
LYNPARZA™ approved by the US food and drug administration for the treatment of advanced ovarian cancer in patients with germline BRCA-mutations
LYNPARZA™ approved by the US food and drug administration for the treatment of advanced ovarian cancer in patients with germline BRCA-mutations
Lynparza™ (olaparib) receives positive CHMP opinion in the EU for the maintenance treatment of BRCA-mutated platinum sensitive relapsed ovarian cancer
Lynparza™ (olaparib) receives positive CHMP opinion in the EU for the maintenance treatment of BRCA-mutated platinum sensitive relapsed ovarian cancer